Search results
FDA approves generic Emflaza oral suspension for Duchenne muscular dystrophy
Medical Xpress· 1 day agoThe U.S. Food and Drug Administration has approved the first generic version of Emflaza...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 6 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical ...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 6 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said late Wednesday that ...
Pfizer 'can't rule out' layoffs in North Carolina after gene therapy flub - Triangle Business...
The Business Journals· 6 hours agoLayoffs could by on the way at Pfizer's massive facility in Sanford after the company's gene therapy...
Study finds LED therapy and antioxidant drug benefit muscle regeneration in Duchenne muscular ...
Medical Xpress· 4 days agoAs reported in an article published in the journal PLOS ONE, the strategy prevented muscle...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 6 days ago(NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 5 days agoSECTORFOCUS BLOG A second failure of a late-stage trial testing a gene therapy to treat Duchenne ...
Sarepta Jumps After Rival Gene Therapy From Pfizer Flops
Investor's Business Daily· 5 days agoThe news gives Sarepta Therapeutics (SRPT) an edge heading to June 21, when the Food and Drug Administration will decide whether to fully approve Elevidys for patients with the muscle-wasting ...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 6 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 6 days agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...